Dr. Fran's hormone testing claims during HRT, fact-checked

What does this video actually claim?

Dr. Fran (@pagingdrfran) argues that testing hormone levels during hormone replacement therapy is unnecessary and potentially misleading. She explains that when you're taking external hormones, blood tests don't accurately reflect what's happening at the tissue level.

The video suggests that symptom management should guide HRT dosing rather than lab values. This challenges the common patient expectation that hormone levels need regular monitoring during treatment.

Does the science back this up?

The evidence largely supports Dr. Fran's position, though with some nuance. The 2022 Menopause Society position statement explicitly states that hormone levels shouldn't guide HRT dosing decisions.

Here's why: serum estradiol levels on oral estrogen don't correlate with tissue exposure due to first-pass metabolism. The WHI follow-up studies (Manson et al., NEJM, 2013) showed benefits were tied to symptom relief, not specific blood levels.

For transdermal estrogen, levels are more predictable but still shouldn't drive dosing. The KEEPS trial (Harman et al., Menopause, 2014) found that symptom improvement occurred across a wide range of measured estradiol levels, from 20-80 pg/mL.

What did she get right?

Dr. Fran correctly identifies that external hormone administration fundamentally changes how we interpret lab values. When you take estradiol, your ovaries shut down natural production through negative feedback.

She's also right that tissue-level hormone activity matters more than blood levels. The ELITE trial (Hodis et al., NEJM, 2016) demonstrated that cardiovascular benefits appeared based on timing and symptoms, not achieving specific estradiol targets.

Her emphasis on symptom-based dosing matches current clinical guidelines. The North American Menopause Society recommends titrating to the lowest effective dose for symptom control, not lab targets.

Where this gets complicated

Dr. Fran oversimplifies slightly. Some situations do warrant hormone testing during HRT, though they're exceptions rather than the rule.

Safety monitoring can be valuable. The ESTHER study (Olie et al., Circulation, 2007) showed that very high estradiol levels (above 100 pg/mL) increased thrombosis risk, making occasional checks reasonable for some patients.

Testosterone monitoring in women receiving testosterone therapy does matter. The Global Consensus Statement (Davis et al., Climacteric, 2019) recommends keeping testosterone levels in the upper half of the premenopausal range to avoid virilization.

What should you actually know?

Don't expect your doctor to chase specific hormone numbers during HRT. The goal is symptom relief with the lowest effective dose, typically starting with 0.5mg oral estradiol or 0.025mg transdermal patches.

Your symptoms tell the real story. Hot flashes, sleep quality, mood, and vaginal dryness are better indicators of adequate dosing than any lab value.

The exception is safety labs. Your doctor should monitor liver function, lipids, and consider mammograms based on standard screening guidelines, but these aren't about hormone levels themselves.